CAJ | 학술논문

目的：探讨芪苈强心胶囊治疗慢性充血性心力衰竭（CHF）的临床疗效并评估其对患者血浆脂联素水平的影响。方法将106例慢性CHF患者随机分为对照组和观察组，各53例。对照组患者采用强心、扩管、利尿等常规治疗，观察组患者在对照组基础上加用芪苈强心胶囊。观察两组患者治疗后的临床疗效、左室射血分数（LVEF），血浆脂联素、脑钠肽（BNP）水平及药品不良反应发生情况。结果观察组患者的总有效率为83.02%，明显高于对照组的73.58%（ P﹤0.05）；两组患者治疗后LVEF均较治疗前明显提高，且观察组提高更明显（ P﹤0.05）；两组患者治疗后血浆脂联素及BNP水平均较治疗前明显降低，且观察组降低更明显（ P﹤0.05）；两组患者的药品不良反应发生率比较，未见明显差异（ P﹥0.05）。结论芪苈强心胶囊治疗慢性CHF疗效确切，且安全性好，同时能显著降低患者血浆脂联素水平，值得临床推广。
목적：탐토기력강심효낭치료만성충혈성심력쇠갈（CHF）적림상료효병평고기대환자혈장지련소수평적영향。방법장106례만성CHF환자수궤분위대조조화관찰조，각53례。대조조환자채용강심、확관、이뇨등상규치료，관찰조환자재대조조기출상가용기력강심효낭。관찰량조환자치료후적림상료효、좌실사혈분수（LVEF），혈장지련소、뇌납태（BNP）수평급약품불량반응발생정황。결과관찰조환자적총유효솔위83.02%，명현고우대조조적73.58%（ P﹤0.05）；량조환자치료후LVEF균교치료전명현제고，차관찰조제고경명현（ P﹤0.05）；량조환자치료후혈장지련소급BNP수평균교치료전명현강저，차관찰조강저경명현（ P﹤0.05）；량조환자적약품불량반응발생솔비교，미견명현차이（ P﹥0.05）。결론기력강심효낭치료만성CHF료효학절，차안전성호，동시능현저강저환자혈장지련소수평，치득림상추엄。
Objective To investigate the clinical efficacy of Qiliqiangxin Capsule in treating chronic congestive heart failure(CHF) and to evaluate its influence on plasma adiponectin level. Methods Totally 106 patients with chronic CHF were randomly divided into the control group and the observation group,53 cases in each group. The control group used the routine therapy of strong heart,diuresis,ex-panding tube,etc. ,while on this basis the observation group was added with Qiliqiangxin Capsule. The clinical efficacy,left ventricular ejection fraction(LVEF),plasma adiponectin and brain natriuretic peptide(BNP) levels were observed in the two groups. In addition,the related adverse drug reactions during the treatment process were observed in the two groups. Results The total effective rate in the ob-servation group was 83. 02%,which was significantly higher than 73. 58% in the control group( P ﹤ 0. 05);LVEF after treatment was significantly increased compared with before treatment,moreover the improvement in the observation group was more obvious( P ﹤ 0. 05);the plasma adiponectin and BNP levels after treatment in the two groups were significantly decreased compared with before treatment, moreover the improvement in the observation group was more obvious( P ﹤ 0. 05);the occurrence rate of adverse reactions had no sta-tistical difference between the two groups ( P ﹥ 0. 05 ) . Conclusion Qiliqiangxin Capsule has definite effect for treating chronic CHF with good safety,at the same time can significantly decrease the plasma adiponectin level and deserves to be promoted in clinic.